$MRNA

Moderna MRNA shares rose 38% since late September as it prepares to present additional Phase 3 trial data for its cancer vaccine, developed with Merck MRK, at the European Society for Medical Oncology Congress. Analysts remain divided, with some issuing Sell ratings due to valuation concerns and others recommending Strong Buy based on potential upside.

Moderna's stock rose 6% to $239.74, outpacing peers BioNTech (up 2% to $90.10) and Pfizer (up 2% to $29.65), amid a sector-wide healthcare rally. The iShares Biotechnology ETF gained 3% to $208.35, while the broader market remained unchanged. The rotation into healthcare follows a shift away from AI and technology sectors, with Moderna benefiting from positive trial data reported in August.

Moderna reported a net loss of $2.8B and revenue of $1.9B for FY 2025, with a 39.2% revenue decline due to reduced COVID-19 product demand. Vertex Pharmaceuticals reported a net income of $4B and revenue of $12.1B, with a 9.6% revenue growth. Both companies face distinct business risks and financial profiles.

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

Goldman Sachs raised its price target for Moderna (MRNA) to $137 from $120, maintaining a Neutral rating. The firm cited upcoming Phase 3 results for melanoma and Phase 1 data for pancreatic cancer as key catalysts. TipRanks identified three Vanguard ETFs (VO, VNQ, VBR) with potential upside, based on analyst consensus and price targets.

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

Moderna and MSD announced successful Phase III trial results for a personalized mRNA cancer vaccine, showing reduced melanoma recurrence. Roche and BioNTech halted a Phase II trial for colorectal cancer. Moderna's shares surged 60%, MSD's rose 6%. Analysts discuss implications for Swiss pharma giants Roche and Novartis, focusing on trial differences and market potential. Challenges include manufacturing time and cost.

Moderna (MRNA) saw $2.36 billion in net ETF buying on Oct. 9, led by Invesco QQQ Trust (QQQ) with $1.87 billion. This extended a four-day buying streak. Moderna's market cap is $85.3 billion, with trailing-12-month revenue of $2.23 billion, down 27.3% year-over-year.

Health Canada is reviewing Moderna's mRNA flu vaccine, mFlusiva, which has been approved in the U.S. and shown 27% greater effectiveness than traditional vaccines. Clinical trials with over 40,000 adults aged 50+ found lower flu-like illness rates. Decision expected this year, with potential variations in availability and cost.

Moderna (MRNA) stock has surged 621% in the past year, despite declining sales and heavy reliance on COVID vaccines. The company's potential growth hinges on intismeran autogene, a cancer therapy in development with Merck, which has shown promise in a Phase 3 trial. Moderna is preparing for a potential launch, but the therapy is not yet on sale. The company's revenue was $2.2 billion in the last year, with COVID vaccines making up 93% of sales.